Update on biologicals for treatment of juvenile idiopathic arthritis. - Test2 - elhamkhani - TriplyDB

Update on biologicals for treatment of juvenile idiopathic arthritis.

Update on biologicals for treatment of juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q38071693

about

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis Intravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: an innovative clinical research approach.Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside.IL-6 as a druggable target in psoriasis: focus on pustular variants.Predictors of response to methotrexate in juvenile idiopathic arthritis.The development and assessment of biological treatments for children.Intravenous laser blood irradiation and tocilizumab in a patient with juvenile arthritis Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.Monoclonal antibody treatments for rheumatoid arthritis.Pediatric uveitis: new and future treatments.New age of biological therapies in paediatric rheumatology.Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.Management of pediatric uveitis.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Republished: new age of biological therapies in paediatric rheumatology.The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock.Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.

P2860

Q26991741-CF5B94B8-17D8-4825-B728-241F1FB1A671 Q28080084-D6DAF273-1D7F-4ABA-AC48-FA5BD1DE9B88 Q31130038-209403B8-6EE7-4009-93BE-2841B95AFE9F Q33622723-1CB934C8-8A3A-4609-89FB-31BB9FAF4DFC Q34003280-E408441C-3810-4215-B100-C1531DB421BD Q34069374-92CA848A-D054-45D7-9627-E56D1591C636 Q35135936-F32C9214-0C49-4D98-878C-2194F688CF67 Q35143297-6725297D-FA7B-42D1-99E7-9A533AFBB55B Q35147847-BEA6E41C-8622-4C6A-B0E2-AF61730BED4D Q37195338-258C4F69-5F16-4D2F-BF46-410479AD6FDC Q38116065-B8F43C52-9CD8-422A-9D16-07533380329E Q38123032-AFC5BB6C-B2F7-41DD-A9CD-2A96BA533CE5 Q38195363-C3D1EE20-EA99-4965-BE39-C51FDEA878CD Q38214382-DE63CACF-D8F7-4183-8178-EC01013C1EA2 Q38225872-8D28BE13-47F9-42C4-A494-F384A1923A54 Q38238947-2B78D0D4-4E8D-4CA4-A504-B801BD983F23 Q38250593-63AEA341-CC96-4A7B-96A5-20146B6E5CDE Q38672339-1B5B7528-D38B-452A-8808-F940B41BC4B4 Q49092664-41272CDC-A361-44BE-B776-B55F1782E56A Q51759532-E07E291C-5662-4498-BF4D-65E41E1CAA80

P2860

Update on biologicals for treatment of juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q38071693

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Update on biologicals for treatment of juvenile idiopathic arthritis.

@en

type

label

Update on biologicals for treatment of juvenile idiopathic arthritis.

@en

prefLabel

Update on biologicals for treatment of juvenile idiopathic arthritis.

@en

P1433

Q38071693-8C5CB946-358F-4D0A-8C42-B9F7A22F862A

P1476

Q38071693-0DCBCD30-90F4-4808-B68D-3538CB9604F5

P2093

Q38071693-494AB8D6-B1A3-4C21-BCF6-8F4A5333381A

P2860

Q38071693-055BC8F9-ED47-4AC7-B37F-A73A6C81B985

Q38071693-0B63A467-5134-493F-A4A5-DD643D125867

Q38071693-0D837A5A-0566-4ADB-9BD1-D83E079BC142

Q38071693-1CBB0152-C6BC-47CB-83FA-FD09A6AA4388

Q38071693-1D7AC378-EEB9-40EE-BA09-5EB80652984C

Q38071693-30053644-D0A2-47DA-8522-A0F75C1FD13D

Q38071693-3AFA8309-6DC4-4ECA-9AD0-C45B177DC8A0

Q38071693-430E4D86-0A49-4EA2-8C40-DC94A2FC23EC

Q38071693-462850F0-D973-4111-8A99-01597C3988CF

Q38071693-47352CB9-155C-4611-8D6B-03F1A8B4B3FF

P304

Q38071693-5E02194B-1CD3-4790-B6D2-6C1EFB458420

P31

Q38071693-F2DFAAA2-14FD-4FFF-84E4-8F899CD2F797

P356

Q38071693-1276F842-6F0E-4C13-A87F-589D69493078

P407

Q38071693-1BD4E88C-A61A-42FA-AA33-17FC1EB5140D

P433

Q38071693-498BA250-BB02-44BE-A313-0EFFE6973EA5

P478

Q38071693-09AA5CA4-E5A1-4B1A-A09F-7A32857E54EB

P577

Q38071693-3DE3A85F-0E94-4958-A061-A5A31101B384

P698

Q38071693-3FBD28D4-0ABB-421F-BD1D-CD9AE2F7228F

P921

Q38071693-8FC2A8C2-EA94-4684-ACAB-01EECBF16FBA

P356

14712598.2013.735657

P1433

Expert Opinion on Biological Therapy

P1476

Update on biologicals for treatment of juvenile idiopathic arthritis.

@en

P2093

Gerd Horneff

http://www.w3.org/2001/XMLSchema#string

P2860

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

Certolizumab pegol for the treatment of Crohn's disease

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

P304

361-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2013.735657

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23289865

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis